ReviewNature reviews. Clinical oncology2015
Clinical management of breast cancer heterogeneity.
Review in Nature reviews. Clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04920708 (Randomised Open-label Phase II Study of Induction Standard of Care Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression), which is not on this map. Cited by 331 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomised Open-label Phase II Study of Induction Standard of Care Fulvestrant and CDK4/6 Inhibition With the Addition of Ipatasertib in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression
Who cites it
331 citing papers in PubMed, 1 synthesis or guideline pooled it, 562 citations in OpenAlex.
- Association Between theFrontiers in genetics · 2022Pooled it
- Noninvasive assessment of breast cancer molecular subtypes on multiparametric MRI using convolutional neural network with transfer learning.Thoracic cancer · 2022Trial
- Predicting the molecular subtype of breast cancer and identifying interpretable imaging features using machine learning algorithms.European radiology · 2022Trial
- Multicenter Randomized Open-Label Phase II Clinical Study Comparing Outcomes of NK105 and Paclitaxel in Advanced or Recurrent Breast Cancer.International journal of nanomedicine · 2022Trial
- HER2 status change in residual breast carcinoma after neoadjuvant HER2-targeted therapy in patients with HER2-positive breast cancer.Breast cancer research and treatment · 2026Article
- Spatial habitat radiomics predicts tertiary lymphoid structure status and identifies an IDO1Journal for immunotherapy of cancer · 2026Article
- Pretreatment Ki67-to-ADC Ratio Predicts Prognosis in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: A Retrospective Cohort Study.Current oncology (Toronto, Ont.) · 2026Article
- Article
- Transcriptional Heterogeneity Underlying Cancer Cell Migration Converges on Shared Regulatory Programs.Genes · 2026Article
- Adipocyte-Derived Palmitic Acid Promotes Breast Cancer Malignancy via ZDHHC15-Mediated S-Palmitoylation of PPARγ.Cancer science · 2026Article
- Added value of intravoxel incoherent motion histogram analysis in differentiating HER2-zero, HER2-low, and HER2-positive breast cancer.La Radiologia medica · 2026Article
- Baseline and Early-Delta Quantitative Ultrasound Radiomics for Predicting Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.Journal of clinical medicine · 2026Article
- HDHD5 promotes triple-negative breast cancer growth and drives EMT-associated phenotypes via regulating S100A4.Journal of cancer research and clinical oncology · 2026Article
- Article
- The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer.Cancer biology & medicine · 2026Review
- Unmasking intratumoral heterogeneity: Postoperative revelation of subclonal divergence inMolecular and clinical oncology · 2026Article
- Heterogeneity and immune microenvironment of early invasive estrogen receptor-positive breast cancer reveal an immune-rich subset.NPJ breast cancer · 2026Article
- Time-Dependent DCE-MRI Radiomics to Predict Response to Neoadjuvant Therapy in Breast Cancer: A Multicenter Study with External Validation.Diagnostics (Basel, Switzerland) · 2026Article
- Identification and Localization of Breast Tumor Components via a Convolutional Neural Network Based on High-Frequency Ultrasound Combined With Histopathologic Registration: Prospective Study.JMIR medical informatics · 2026Article
- Assessment of the anticancer and antimetastatic effects of monocarbonyl analogs of curcumin, C66 and B2BrBC, in breast cancer cells.Cancer cell international · 2026Article
271 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
Abstract
Traditionally, intertumour heterogeneity in breast cancer has been documented in terms of different histological subtypes, treatment sensitivity profiles, and clinical outcomes among different patients. Results of high-throughput molecular profiling studies have subsequently revealed the true extent of this heterogeneity. Further complicating this scenario, the heterogeneous expression of the oestrogen receptor (ER), progesterone receptor (PR), and HER2 has been reported in different areas of the same tumour. Furthermore, discordance, in terms of ER, PR and HER2 expression, has also been reported between primary tumours and their matched metastatic lesions. High-throughput molecular profiling studies have confirmed that spatial and temporal intratumour heterogeneity of breast cancers exist at a level beyond common expectations. We describe the different levels of tumour heterogeneity, and discuss the strategies that can be adopted by clinicians to tackle treatment response and resistance issues associated with such heterogeneity, including a rationally selected combination of agents that target driver mutations, the targeting of deleterious passenger mutations, identifying and eradicating the 'lethal' clone, targeting the tumour microenvironment, or using adaptive treatments and immunotherapy. The identification of the most-appropriate strategies and their implementation in the clinic will prove highly challenging and necessitate the adoption of radically new practices for the optimal clinical management of breast malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.